Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease	Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder	Active, not recruiting	Phase 2 / Phase 3	2026-05-01		NCT06873334

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Skyhawk Therapeutics, Inc.	3

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Auckland City Hospital	Auckland	New Zealand	68
Calvary Health Care Bethlehem	Caulfield South	Australia	2
Christchurch Neurology Trials Limited	Christchurch	New Zealand	1
Flinders Medical Centre	Adelaide	Australia	14
Huntington's Disease Association	Auckland	New Zealand	2
John Hunter Hospital	New Lambton Heights	Australia	24
Launceston General Hospital	Launceston	Australia	8
The Perron Institute for Neurology and Translational Science (Perron Institute)	Nedlands	Australia	2
The Royal Melbourne Hospital	Parkville	Australia	26
The University of Queensland	Herston	Australia	2
Wellington Hospital	Wellington	New Zealand	12
Westmead Hospital	Westmead	Australia	128